AstraZeneca, Isis unite to develop antisense cancer drugs

12/12/2012 | Reuters · Genetic Engineering & Biotechnology News

Isis Pharmaceuticals and AstraZeneca agreed to jointly discover and develop antisense treatments against five cancer targets. The agreement also covers rights to develop and market Isis' experimental drug ISIS-STAT3Rx, which is in Phase I development for patients with advanced lymphomas. The deal entitles Isis to $31 million upfront and near-term fees, plus potential licensing and milestone payments and sales royalties.

View Full Article in:

Reuters · Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice President - Government Products
Health Alliance Plan
Detroit, MI
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
Actuary
Meridian Health Plan
Detroit, MI
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
President/Chief Executive Officer
MedCost
Winston-Salem, NC